Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

Renal failure in multiple myeloma typically occurs when the kidneys fail to filter waste products from the blood, leading to ...

Most had prior exposure to anti-CD38 antibodies, immunomodulatory drugs ... and cytokine release syndrome, which was mostly low grade. Only one case of grade 1 ICANS was reported, and one ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

You may develop low diastolic blood pressure due to certain medications or aging. You can also have low diastolic blood pressure if you have low blood pressure overall. The medical term for low ...

Last month however saw the approval of its first direct competitor – Sanofi’s anti-CD38 antibody Sarclisa (isatuximab) – which was given the nod by the FDA as a third-line therapy for myeloma.

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

President Donald Trump’s net approval rating has increased nine points since it reached a low point in April in the latest Economist/YouGov survey—as his poll numbers are slightly above his ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...